U.S., Jan. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07317505) titled 'A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors' on Nov. 25, 2025.
Brief Summary: The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors.
The main questions it aims to answer are:
* To assess the safety and tolerability of JMT108 at increasing doses and determine the dose and schedule to be used in the second part of the study (Phase 1a)
* To assess effectiveness of JMT108 in participants with locally advanced or metastatic tumors (Phase 1b)
* To evaluate how quickly JMT108 is metabolized by the body (ph...